Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aritinercept in generalized myasthenia gravis
2025-525127-27-00Phase 2Authorised
- Sponsor
- Aurinia
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing AUR200 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events and Change from baseline in MG-ADL total score. Planned start Jun 2026; status: authorised.
02
Drugs
aritinercept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-525127-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525127-27-00.